| Dr Najindra Maharjan, MD | |
|
811 Se 28th St, Suite 7, Bentonville, AR 72712-4268 | |
| (479) 271-9393 | |
| (479) 271-0141 |
| Full Name | Dr Najindra Maharjan |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 17 Years |
| Location | 811 Se 28th St, Bentonville, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144485129 | NPI | - | NPPES |
| 20120886 | Other | NM | LICENSE |
| 27387 | Other | NE | LICENSE |
| E-8323 | Other | AR | AR MEDICAL LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excelsior Springs Dialysis | Excelsior springs, MO | Dialysis facility |
| Liberty Dialysis | Liberty, MO | Dialysis facility |
| Northland Dialysis | North kansas city, MO | Dialysis facility |
| Swope Dialysis | Kansas city, MO | Dialysis facility |
| North Kansas City Hospital | North kansas city, MO | Hospital |
| New Liberty Hospital District | Liberty, MO | Hospital |
| Excelsior Springs Hospital | Excelsior springs, MO | Hospital |
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Ray County Memorial Hospital | Richmond, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nephrology Associates Md Pa | 9931012820 | 20 |
| Nephrology Associates Md Pa | 9931012820 | 20 |
News Archive
A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
› Verified 4 days ago
| Entity Name | Nephrology Associates Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578696506 PECOS PAC ID: 9931012820 Enrollment ID: O20050721001062 |
News Archive
A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Najindra Maharjan, MD 811 Se 28th St, Suite 7, Bentonville, AR 72712-4268 Ph: (479) 271-9393 | Dr Najindra Maharjan, MD 811 Se 28th St, Suite 7, Bentonville, AR 72712-4268 Ph: (479) 271-9393 |
News Archive
A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
› Verified 4 days ago
Mr. Lance Lee Hamilton, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2618 Se J St, Ste 12, Bentonville, AR 72712 Phone: 479-715-6505 Fax: 479-340-0015 | |
Jose Gregorio Loyo-molina, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy, Suite 240a, Bentonville, AR 72712 Phone: 479-553-2200 Fax: 479-553-2909 | |
Dr. Jamon R Pruitt, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy, Suite 240b, Bentonville, AR 72712 Phone: 479-553-2200 Fax: 479-553-2909 | |
Rupali Abhijit Paradkar, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1000 Se 13th Ct, Bentonville, AR 72712 Phone: 479-273-9056 Fax: 479-273-6937 | |
Daniel Young, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy Ste 240b, Bentonville, AR 72712 Phone: 479-273-9173 | |
Dr. Jason M Bailey, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy Ste 310, Bentonville, AR 72712 Phone: 479-553-3310 Fax: 479-553-1945 |